• Raised $537M through placement and institutional entitlement offer
• Minimum $600M to be raised through the capital raising
• Financing extends cash runway through to CY2030

PYC Therapeutics, a precision medicine company dedicated to developing treatments for genetic diseases, has announced the successful closure of a $653 million capital raising through a placement and entitlement offer. The company received commitments for $537 million under the placement and institutional component of the entitlement offer, with the remaining $116 million to be raised through the retail entitlement offer. The financing has extended PYC's cash runway through to 2030, enabling the company to deliver important human safety and efficacy data for all four of its drug development programs. The placement was supported by leading US specialist life sciences investors, while the entitlement offer attracted strong participation from existing institutional shareholders. The company has satisfied the condition precedent to the underwriting agreement, ensuring a minimum of $600 million will be raised through the capital raising. The retail entitlement offer will provide eligible retail shareholders the opportunity to participate, with the offer expected to close on February 27, 2026.

The capital raising has extended PYC's cash runway through to CY2030, enabling the company to deliver important human safety and efficacy data for all four of its drug development programs.